Preclinical News and Research

RSS
Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Myotec, Hybrid merge to form PsiOxus Therapeutics

Myotec, Hybrid merge to form PsiOxus Therapeutics

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

Amira's clinical-stage DP2 receptor antagonist program data to be presented at Pacifichem 2010

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

DARPA awards Pulmatrix $5.7 million grant to advance iCALM therapies

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Lack of 'systematic reviews' in stroke research lead to waste of time, resources

Lack of 'systematic reviews' in stroke research lead to waste of time, resources

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

Intercell to stop further development of Travelers' Diarrhea Vaccine Patch

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Vical's Vaxfectin adjuvant boosts immune response of DNA-based vaccines against cancer

Stimatix GI's AOS-C1000 colostomy management device meets primary, secondary endpoints in pre-clinical studies

Stimatix GI's AOS-C1000 colostomy management device meets primary, secondary endpoints in pre-clinical studies

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax reports promising results from entinostat preclinical studies in breast cancer

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

Blocking growth of blood vessels with antibodies could improve treatment of cancerous tumors

Caliper to acquire CRi for $20.0 million

Caliper to acquire CRi for $20.0 million

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

Clinical, preclinical results of ISF35 in CLL patients presented at ASH 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.